Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | BIPARK-I and II: opicapone and levodopa in PD with motor fluctuations

Angelo Antonini • 20 May 2020
EAN 2020
Movement Disorders Parkinson's Disease Levodopa Opicapone
BIPARK-I BIPARK-II

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses a post-hoc analysis of the BIPARK-I and BIPARK-II trials. The results confirm that using a catechol-O-methyltransferase (COMT) inhibitor, such as opicapone, can significantly extend the benefits of levodopa in Parkinson’s disease (PD) patients with motor fluctuations. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Angelo Antonini

1:50
Clinical highlights in Parkinson's disease
Angelo Antonini • 27 Aug 2023
1:29
Benefits and challenges associated with subcutaneous infusions for Parkinson’s disease
Angelo Antonini • 27 Aug 2023
1:11
Wearables: technological advancements in movement disorder management
Angelo Antonini • 1 Jul 2023
1:36
Parkinson's disease: updates in the disease-modifying space
Angelo Antonini • 1 Jul 2023

Related Videos

5:26
Pridopidine shows benefit for patients with early HD not on antidopaminergic therapies
Michael Hayden • 16 Apr 2024
2:51
Overlap in etiology between different FND subtypes
Mark Hallett • 15 Apr 2024
1:58
Ambroxol & other targeted therapies in Parkinson's
K Ray Chaudhuri • 21 Mar 2024
3:00
The use of precision medicine in Parkinson’s disease
K Ray Chaudhuri • 21 Mar 2024
The content of VJNeurology is intended for healthcare professionals